Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating the Role of NSD2 Methyltransferase in Pancreatic Cancer Drug Resistance

EF 2023-24

Résumé
Pancreatic cancer is the fourth-leading cause of cancer-related mortality globally, with the average 5-year survival rate below 8% and projected to become the second-leading cause of cancer-related mortality by 2023. Besides the late disease diagnosis, the poor survival is attributed to the lack of therapeutic options and chemotherapy resistance, thus necessitating novel treatment approaches. Nuclear SET Domain 2 (NSD2) is a histone methyl transferase that di-methylates Histone 3 Lysine 36 (H3K36me2) to catalyze gene transcription. Overexpression of NSD2 promotes cancer formation and regulates key genes required for epithelial-to-mesenchymal transition (EMT) or tumor metastasis. One of the ways cancer cells are able to survive chemotherapy is by promoting EMT, which suppresses pathways to kill newly forming cancer cells. In pancreatic cancer cells, increased expression of EMT is known to contribute to drug resistance, lowering the therapeutical effects of gemcitabine, a chemotherapy agent for pancreatic cancer. Therapeutic targeting of EMT transcripts such as ZEB1 is notoriously difficult but is possible by proteolysis-targeting chimeras (PROTACs) compounds, which allow targeted degradation of NSD2. I will employ a highly selective NSD2 degrader compound UNC8732, to assess how NSD2 regulates EMT and drug resistance of PDAC organoids against chemotherapy. My research will establish the link between NSD2, EMT and drug resistance in PDAC organoids. Furthermore, this work will elucidate the role of NSD2-regulated H3K36me2 levels in conferring PDAC organoid drug resistance. My findings will be integral in assessing the therapeutic potential of NSD2 degraders to overcome drug resistance in PDAC.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
505927
Name
Cheon Sehyun
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Role of NSD2 Methyltransferase in Pancreatic Cancer Drug Resistance
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Resistance; Epithelial To Mesenchymal; Histone Lysine Methyltransferase; Lysine Methylation; Nsd2; Organoid; Pancreatic Cancer; Protac
Abstract
Pancreatic cancer is the fourth-leading cause of cancer-related mortality globally, with the average 5-year survival rate below 8% and projected to become the second-leading cause of cancer-related mortality by 2023. Besides the late disease diagnosis, the poor survival is attributed to the lack of therapeutic options and chemotherapy resistance, thus necessitating novel treatment approaches. Nuclear SET Domain 2 (NSD2) is a histone methyl transferase that di-methylates Histone 3 Lysine 36 (H3K36me2) to catalyze gene transcription. Overexpression of NSD2 promotes cancer formation and regulates key genes required for epithelial-to-mesenchymal transition (EMT) or tumor metastasis. One of the ways cancer cells are able to survive chemotherapy is by promoting EMT, which suppresses pathways to kill newly forming cancer cells. In pancreatic cancer cells, increased expression of EMT is known to contribute to drug resistance, lowering the therapeutical effects of gemcitabine, a chemotherapy agent for pancreatic cancer. Therapeutic targeting of EMT transcripts such as ZEB1 is notoriously difficult but is possible by proteolysis-targeting chimeras (PROTACs) compounds, which allow targeted degradation of NSD2. I will employ a highly selective NSD2 degrader compound UNC8732, to assess how NSD2 regulates EMT and drug resistance of PDAC organoids against chemotherapy. My research will establish the link between NSD2, EMT and drug resistance in PDAC organoids. Furthermore, this work will elucidate the role of NSD2-regulated H3K36me2 levels in conferring PDAC organoid drug resistance. My findings will be integral in assessing the therapeutic potential of NSD2 degraders to overcome drug resistance in PDAC.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheon, Sehyun
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~